The basis on which India approves precaution dose remains unclear
He said the primary focus of the government was on giving a second dose of the vaccine to make people fully vaccinated. “Administering the second dose of COVID-19 vaccine to…
Category: Emergency use authorisation
Two COVID-19 antivirals get FDA nod for emergency use
Unlike in the case of remdesivir, both the drugs — Pfizer’s paxlovid and Merck’s molnupiravir — are oral pills and so can be administered outside hospital settings. These drugs are…
Soon mRNA vaccines for young children who rarely suffer from severe disease
On September 20, Pfizer released details of the trial that showed the vaccine was safe and generated a “robust” antibody response in young children. Going by past experience, the FDA…
Government passes off factually incorrect vaccination information as ‘fact’
According to the PIB release, the myth was that the Centre wasn’t taking any step to vaccinate children. Clarifying this, Dr. Paul said: “As of now, no country in the…
India sets a dangerous precedent with COVID-19 vaccination programme
A large percentage of those aged 18-44 years does not have the resources to pay for vaccines and hence will fall through the cracks. So, the States will have to…
Should Covaxin trial continue till 130 cases are recorded?
According to details posted on the clinical trial registry, the company had planned to “continue the phase-3 trial until 130 study participants developed PCR-confirmed symptomatic COVID-19 disease during follow-up beginning…
Covaxin should no longer be available in ‘clinical trial mode’
The vaccine efficacy was measured based on symptomatic COVID-19 disease — mild, moderate or severe — two weeks after the second dose. The interim analysis undertaken at the first endpoint…
Pfizer vaccine can be stored at -15 to -25 degree C for two weeks
On December 11, 2020 when the U.S. FDA approved the vaccine for emergency use, the storage temperature stipulated was -60 to -80 degree C. The labels for the vaccine too…
Science Chronicle 